Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 13, 2018

J&J accepts Platinum Equity’s $2.1bn offer to buy LifeScan

Johnson & Johnson (J&J) has accepted private investment firm Platinum Equity’s binding offer to acquire its subsidiary LifeScan for around $2.1bn.

Johnson & Johnson (J&J) has accepted private investment firm Platinum Equity’s binding offer to acquire its subsidiary LifeScan for around $2.1bn.

The decision follows consultation with associated works councils and trade unions. This offer was originally proposed in March this year and is subject to customary closing conditions and regulatory clearances.

LifeScan offers blood glucose monitoring systems under the brand OneTouch to allow diabetes management. Its products are designed for simple and accurate testing at hospitals as well as home.

“Platinum Equity plans to leverage its financial resources and operating expertise to support LifeScan’s goal to enhance the quality of life of diabetes patients.”

Used by nearly 20 million patients across more than 90 countries, OneTouch products include glucose metres and accessories, insulin pumps, testing strips, lancets, point-of-care systems for testing and integrated digital solutions.

The company reported net revenue of around $1.5bn last year.

Platinum Equity plans to leverage its financial resources and operating expertise to support LifeScan’s goal to enhance the quality of life of diabetes patients.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

After the completion of the transaction, which is scheduled to complete by the end of this year, LifeScan will operate as a global standalone business and provide a platform for continued investment to boost growth and innovation.

A statement from J&J read: “The Johnson & Johnson Family of Companies will continue to serve those impacted by diabetes through innovative products, services and solutions from its Medical Device, Pharmaceuticals and Consumer businesses.

“These include important leadership and innovation in areas such as bariatric surgery and through medicines such as INVOKANA (canagliflozin) and INVOKAMET (canagliflozin/metformin HCl).”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU